Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last?
Moderna (MRNA) stock exploded 177% on melanoma vaccine trial success, marking the biggest S&P 500 gain in 20+ years. Analysts question if it's sustainable.
The post Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last? appeared first on Blockonomi.
Source: Source: Blockonomi